Back to OAKTREE CAPITAL MANAGEMENT LP OAKTREE CAPITAL MANAGEMENT LP

BTAIQBTAIQ
5 quarters

Position history for OAKTREE CAPITAL MANAGEMENT LPOAKTREE CAPITAL MANAGEMENT LP's holdings in BioXcel Therapeutics, Inc.

Yes. Oaktree Capital Management holds 1,380,248 shares of BTAIQ (BioXcel Therapeutics), worth $1.9M, as of its Q2 2026 13F filing. It increased the position from 241,188 shares in Q1 2026. Oaktree Capital Management has held BTAIQ since Q2 2025, across 5 quarterly 13F filings.

Current Value

$1.9M

Current Shares

1.4M

Total Value Change

+$1.5M

Total Shares Change

+1.1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.4M
+472.3%
$1.9M0.0%$1.41
42
2026-Q1
Unchanged
241,188
0.0%
$323,1930.0%$1.34
0
2025-Q4
Unchanged
241,188
0.0%
$385,9020.0%$1.60
0
2025-Q3
Unchanged
241,188
0.0%
$617,4430.0%$2.56
0
2025-Q2
New
241,188
-
$436,5510.0%$1.81
33

Other major holders of BTAIQ: MILLENNIUM MANAGEMENT LLC, VANGUARD CAPITAL MANAGEMENT LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used